查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
阿茲海默症生物標記診斷市場－全球及區域分析、各區域 - 分析及預測（2025-2035）
市場調查報告書
商品編碼
1814819

阿茲海默症生物標記診斷市場－全球及區域分析、各區域 - 分析及預測（2025-2035）

Alzheimer Biomarker Based Diagnostic Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035
出版日期: | 出版商: BIS Research | 英文 100 Pages | 商品交期: 1-5個工作天內

價格

全球阿茲海默症生物標記診斷市場 - 分析與預測（2025-2035）

基於生物標記的阿茲海默症診斷是一種先進的醫療方法，致力於識別特定的生物標記物，例如澱粉樣蛋白斑塊、神經纖維纏結和其他與阿茲海默症（AD）相關的蛋白質。

這些生物標記存在於血液和腦脊髓液（CSF）等體液中，或透過腦部影像技術發現，可為了解疾病的存在、進展和嚴重程度提供重要見解。

基於生物標記的診斷的主要目標是早期發現，以便在認知能力嚴重下降之前及時介入。腦脊髓液分析、血液檢測以及正子斷層掃描（PET）和磁振造影（MRI）等影像技術是這個過程的核心。雖然這些方法提高了診斷準確性並實現了個人化治療方案，但仍存在挑戰，包括高成本、可及性和監管核准。然而，該領域快速發展，發現的新生物標記越多，更有效、更廣泛的早期檢測的可能性就越大，這為阿茲海默症的治療帶來更好的結果。

阿茲海默症生物標記診斷市場的主要驅動力之一是全球人口老化導致阿茲海默症率不斷上升。隨著預期壽命的延長，阿茲海默症患者數量顯著增加，對有效診斷工具的需求也日益迫切。

早期準確的診斷對於控制這種疾病非常重要，因此對基於生物標記的診斷技術的需求日益成長。這些技術能夠在症狀出現之前及早發現，因此有可能實現及時介入和更個人化的治療。這種日益流行的趨勢以及對早期診斷的追求推動研發投入，並加速基於生物標記的診斷技術在臨床實踐中的應用。

阿茲海默症生物標記診斷市場面臨的關鍵挑戰之一是先進診斷技術的高昂成本和有限的可及性。許多最準確的方法，例如腦脊髓液（CSF）分析、正子斷層掃描（PET）掃描和先進的血液檢測，價格昂貴，且並非所有醫療機構都能輕易獲得，尤其是在資源匱乏的農村地區。這限制了這些診斷工具的廣泛應用，並使其無法惠及那些可能受益於早期檢測的廣大患者族群。

此外，這些診斷方法的高昂成本可能會限制患者獲得診斷服務，尤其是在醫療資源匱乏或保險覆蓋有限的地區。如何讓這些診斷方法更經濟實惠、更容易獲取，仍然是充分發揮其市場潛力的一大障礙。

全球阿茲海默症標記診斷市場競爭激烈，多家主要企業推動技術創新和市場成長。包括 Quanterix、Fujirebio Diagnostics、C2N Diagnostics、Lantheus Holdings Inc.、Sysmex Corporation、Quest Diagnostics Inc. 和 Siemens Healthineers AG 在內的主要企業處於開發和商業化診斷解決方案的前沿。這些公司致力於提高阿茲海默症診斷的準確性、效率和可及性，其中許多公司投資於血液生物標記、影像技術和人工智慧診斷工具等最尖端科技。這些創新目的是應對早期發現、降低成本和個人化治療策略等挑戰。透過策略夥伴關係、收購和持續研究，這些公司塑造阿茲海默症診斷的未來，並競爭以佔領不斷成長的市場的很大佔有率。

阿茲海默症生物標記診斷市場細分

細分1：依地區

  • 北美洲
  • 歐洲
  • 亞太地區
  • 其他地區

全球阿茲海默症生物標記診斷市場最重要的新興趨勢之一是血液生物標記檢測在阿茲海默症早期檢測中的進步和廣泛應用。這些檢測提供了一種侵入性較小、成本效益更高且擴充性的替代方案，可取代腦脊髓液（CSF）分析和正子斷層掃描（PET）等傳統方法。特別是，Roche的Elecsys pTau217 等血液檢測已證明其診斷準確性可與 PET 和 CSF 檢測相媲美，標誌著臨床診斷領域的一個重要里程碑。這些檢測能夠在阿茲海默症出現嚴重認知衰退之前進行早期檢測，為早期療育提供了重要機會。

此外，血液診斷技術在臨床試驗中發展動力強勁，為確定合適的緩解疾病治療候選藥物提供了更便捷的方法。這一趨勢不僅提高了阿茲海默症診斷的準確性，也使檢測更加經濟實惠、便捷易得，這對於全球推廣非常重要，尤其是在醫療資源匱乏的地區。隨著這些技術的不斷發展和獲得監管部門的核准，它們有望徹底改變阿茲海默症的檢測和管理，最終改善患者的預後。

目錄

執行摘要

第1章 全球阿茲海默症生物標記診斷市場：產業展望

  • 介紹
  • 市場趨勢
  • 法律規範
  • 流行病學分析
  • 臨床試驗分析
  • 市場動態

第2章 2024-2035年全球阿茲海默症生物標記診斷市場（依地區）

  • 北美洲
  • 歐洲
  • 亞太地區

第3章 全球阿茲海默症生物標記診斷市場：競爭格局與公司概況

  • 關鍵策略和發展
  • 公司簡介
    • Quanterix Corporation
    • Fujirebio Diagnostics
    • Lantheus Holdings Inc.
    • Sysmex Corporation
    • Quest Diagnostics Inc.
    • Siemens Healthineers AG

第4章 調查方法

Product Code: BHL3249SA

Global Alzheimer Biomarker Based Diagnostic Market, Analysis and Forecast: 2025-2035

Alzheimer biomarker-based diagnostics is an advanced medical approach focused on identifying specific biomarkers such as amyloid plaques, tau tangles, and other proteins associated with Alzheimer's disease (AD). These biomarkers, found in biological fluids like blood or cerebrospinal fluid (CSF) or through brain imaging techniques, provide crucial insights into the disease's presence, progression, and severity.

The primary goal of biomarker-based diagnostics is early detection, allowing for timely intervention before significant cognitive decline occurs. Techniques like CSF analysis, blood tests, and imaging methods such as positron emission tomography (PET) and magnetic resonance imaging (MRI) are central to this process. While these methods improve diagnostic accuracy and enable personalized treatment plans, challenges such as high costs, accessibility, and regulatory approval remain. However, the field is rapidly evolving, and as new biomarkers are discovered, the potential for more effective and widespread early detection grows, offering hope for better outcomes in managing Alzheimer's disease.

One of the key drivers of the Alzheimer biomarker-based diagnostic market is the increasing prevalence of Alzheimer's disease due to the aging global population. As life expectancy rises, the number of individuals affected by Alzheimer's is growing significantly, creating a pressing need for effective diagnostic tools.

Early and accurate diagnosis is crucial for managing the disease, leading to a higher demand for biomarker-based diagnostics. These technologies enable earlier detection, potentially before symptoms even appear, allowing for timely intervention and more personalized treatment. This growing patient population and the shift towards early-stage diagnosis are driving investments in research and development, as well as accelerating the adoption of biomarker-based diagnostic methods in clinical practice.

One of the primary challenges in the Alzheimer biomarker-based diagnostic market is the high cost and limited accessibility of advanced diagnostic techniques. Many of the most accurate methods, such as cerebrospinal fluid (CSF) analysis, positron emission tomography (PET) scans, and advanced blood tests, are expensive and may not be readily available in all healthcare settings, particularly in low-resource or rural areas. This limits the widespread adoption of these diagnostic tools, preventing them from reaching the broader patient population who could benefit from early detection.

Additionally, the cost burden associated with these diagnostics can restrict access to patients, especially in regions where healthcare systems are underfunded or where insurance coverage is limited. The challenge of making these diagnostics more affordable and accessible remains a significant barrier to the market's full potential.

The global Alzheimer biomarker-based diagnostic market is highly competitive, with several key players driving innovation and market growth. Leading companies such as Quanterix, Fujirebio Diagnostics, C2N Diagnostics, Lantheus Holdings Inc., Sysmex Corporation, Quest Diagnostics Inc., and Siemens Healthineers AG are at the forefront of developing and commercializing diagnostic solutions. These companies are focused on advancing the accuracy, efficiency, and accessibility of Alzheimer's diagnostics, with many investing in cutting-edge technologies like blood-based biomarkers, imaging techniques, and AI-driven diagnostic tools. Their innovations aim to address challenges such as early detection, cost reduction, and personalized treatment strategies. Through strategic partnerships, acquisitions, and continuous research, these companies are shaping the future of Alzheimer's disease diagnostics and competing to capture a significant share of the growing market.

Alzheimer Biomarker Based Diagnostic Market Segmentation:

Segmentation 1: by Region

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

One of the most significant emerging trends in the global Alzheimer biomarker-based diagnostic market is the advancement and widespread adoption of blood-based biomarker tests for the early detection of Alzheimer's disease. These tests offer a less invasive, cost-effective, and scalable alternative to traditional methods like cerebrospinal fluid (CSF) analysis and positron emission tomography (PET) scans. Notably, blood-based tests such as Roche's Elecsys pTau217 have demonstrated diagnostic accuracy comparable to PET scans and CSF assays, marking a major milestone in clinical diagnostics. These tests enable earlier detection of Alzheimer's, often before significant cognitive decline occurs, providing critical opportunities for early intervention.

Furthermore, blood-based diagnostics are gaining momentum in clinical trials, offering a more accessible way to identify suitable candidates for disease-modifying treatments. This trend is not only increasing the accuracy of Alzheimer's diagnoses but also improving the affordability and accessibility of testing, which is crucial for global adoption, particularly in underserved regions. As these technologies continue to evolve and gain regulatory approval, they are expected to revolutionize Alzheimer's disease detection and management, ultimately leading to better outcomes for patients.

Table of Contents

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

1. Global Alzheimer Biomarker Based Diagnostic Market: Industry Outlook

  • 1.1 Introduction
  • 1.2 Market Trends
  • 1.3 Regulatory Framework
  • 1.4 Epidemiology Analysis
  • 1.5 Clinical Trial Analysis
  • 1.6 Market Dynamics
    • 1.6.1 Impact Analysis
    • 1.6.2 Market Drivers
    • 1.6.3 Market Challenges
    • 1.6.4 Market Opportunities

2. Global Alzheimer Biomarker Based Diagnostic Market (by Region), ($Billion), 2024-2035

  • 2.1 North America
    • 2.1.1 Key Findings
    • 2.1.2 Market Dynamics
    • 2.1.3 Market Sizing and Forecast
      • 2.1.3.1 North America Alzheimer Biomarker Based Diagnostic Market, by Country
        • 2.1.3.1.1 U.S.
  • 2.2 Europe
    • 2.2.1 Key Findings
    • 2.2.2 Market Dynamics
    • 2.2.3 Market Sizing and Forecast
      • 2.2.3.1 Europe Alzheimer Biomarker Based Diagnostic Market, by Country
        • 2.2.3.1.1 Germany
        • 2.2.3.1.2 U.K.
        • 2.2.3.1.3 France
        • 2.2.3.1.4 Italy
  • 2.3 Asia Pacific
    • 2.3.1 Key Findings
    • 2.3.2 Market Dynamics
    • 2.3.3 Market Sizing and Forecast
      • 2.3.3.1 Asia Pacific Alzheimer Biomarker Based Diagnostic Market, by Country
        • 2.3.3.1.1 China
        • 2.3.3.1.2 Japan

3. Global Alzheimer Biomarker Based Diagnostic Market: Competitive Landscape and Company Profiles

  • 3.1 Key Strategies and Development
    • 3.1.1 Mergers and Acquisitions
    • 3.1.2 Synergistic Activities
    • 3.1.3 Business Expansions and Funding
    • 3.1.4 Product Launches and Approvals
    • 3.1.5 Other Activities
  • 3.2 Company Profiles
    • 3.2.1 Quanterix Corporation
      • 3.2.1.1 Overview
      • 3.2.1.2 Top Products / Product Portfolio
      • 3.2.1.3 Top Competitors
      • 3.2.1.4 Target Customers/End-Users
      • 3.2.1.5 Key Personnel
      • 3.2.1.6 Analyst View
    • 3.2.2 Fujirebio Diagnostics
      • 3.2.2.1 Overview
      • 3.2.2.2 Top Products / Product Portfolio
      • 3.2.2.3 Top Competitors
      • 3.2.2.4 Target Customers/End-Users
      • 3.2.2.5 Key Personnel
      • 3.2.2.6 Analyst View
    • 3.2.3 Lantheus Holdings Inc.
      • 3.2.3.1 Overview
      • 3.2.3.2 Top Products / Product Portfolio
      • 3.2.3.3 Top Competitors
      • 3.2.3.4 Target Customers/End-Users
      • 3.2.3.5 Key Personnel
      • 3.2.3.6 Analyst View
    • 3.2.4 Sysmex Corporation
      • 3.2.4.1 Overview
      • 3.2.4.2 Top Products / Product Portfolio
      • 3.2.4.3 Top Competitors
      • 3.2.4.4 Target Customers/End-Users
      • 3.2.4.5 Key Personnel
      • 3.2.4.6 Analyst View
    • 3.2.5 Quest Diagnostics Inc.
      • 3.2.5.1 Overview
      • 3.2.5.2 Top Products / Product Portfolio
      • 3.2.5.3 Top Competitors
      • 3.2.5.4 Target Customers/End-Users
      • 3.2.5.5 Key Personnel
      • 3.2.5.6 Analyst View
    • 3.2.6 Siemens Healthineers AG
      • 3.2.6.1 Overview
      • 3.2.6.2 Top Products / Product Portfolio
      • 3.2.6.3 Top Competitors
      • 3.2.6.4 Target Customers/End-Users
      • 3.2.6.5 Key Personnel
      • 3.2.6.6 Analyst View

4. Research Methodology

List of Figures

  • Figure: Global Alzheimer Biomarker Based Diagnostic Market (by Region), $Billion, 2024 and 2035
  • Figure: Global Alzheimer Biomarker Based Diagnostic Market Key Trends, Analysis

List of Tables

  • Table: Global Alzheimer Biomarker Based Diagnostic Market Dynamics, Impact Analysis
  • Table: Global Alzheimer Biomarker Based Diagnostic Market (by Region), $Billion, 2024-2035